Lotilander Provides Clinically Meaningful Demodex Treatment

Lotilaner ophthalmic solution 0.25% is a safe and effective treatment for Demodex blepharitis (DB), according to a poster presented at the 2022 annual meeting of the American Academy of Ophthalmology (AAO) held in Chicago September 30 to October 3. 

The pivotal phase 3 trial evaluated the safety and efficacy of lotilander ophthalmic solution 0.25% in patients with Demodex (N=418). Patients were eligible for Demodex treatment if they had more than 10 collarettes, at least 1.5 mites per lash on upper or lower lids.

For these patients, a single drop of lotilaner, or a vehicle, was applied twice a day in each eye for 43 days without lid intervention. 

Investigators report that a majority of patients experienced a statistically significant (P < .01) and clinically meaningful complete collarette cure (defined as ≤10 collarettes). A reduction in lid erythema and eradication of mites was achieved on or before Day 43 between lotilaner and vehicle. Most patients stated that both lotilaner and vehicle drops were neutral to very comfortable.